Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (684)	4/5/2001 5:17:11 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3044

Thursday April 5, 5:00 pm Eastern Time Press Release SOURCE: Millennium Pharmaceuticals, Inc. Millennium Pharmaceuticals Adopts Shareholder Rights Plan CAMBRIDGE, Mass., April 5 /PRNewswire/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - news) announced today that it has adopted a shareholder rights plan designed to ensure that all Millennium shareholders will receive fair and equal treatment in the event of any unsolicited attempt to acquire the Company. The plan was not adopted in response to any unsolicited offer or takeover attempt. (Photo: newscom.com ) A complete copy of the shareholder rights plan is included in a Current Report on Form 8-K that Millennium filed today with the SEC. In addition, Millennium stockholders of record on April 16, 2001 will be mailed a detailed summary of the rights. Millennium, a leading biopharmaceutical company, applies its comprehensive and integrated science and technology platform for the discovery and development of breakthrough therapeutic and predictive medicine products, with a goal of delivering personalized medicine. Through the industrialization of this gene-to-patient platform, Millennium is also striving to accelerate the process of drug discovery and development. Headquartered in Cambridge, Massachusetts, Millennium currently employs more than 1,300 people. Editor's Note: This release is available on Millennium's website at www.millennium.com SOURCE: Millennium Pharmaceuticals, Inc.